Neurological symptoms associated with COVID-19 based on a nation-wide online survey

Česká verzia

Authors: T. Dvořáková ¹; J. Bušková ^1,2; A. Bartoš ^1,3
Authors place of work: Národní ústav duševního zdraví, Klecany ¹; Klinika psychiatrie a lékařské psychologie 3. LF UK, Praha ²; Neurologická klinika 3. LF UK a FN Královské Vinohrady, Praha ³
Published in the journal: Cesk Slov Neurol N 2022; 85(3): 220-227
Category: Original Paper
doi: https://doi.org/10.48095/cccsnn2022220

Summary

Aim: There are no broad-scale data available on the presence of neurological symptoms in persons afflicted by COVID-19 in the Czech Republic. Therefore, our goal was to establish the incidence, frequency and duration of new neurological symptoms present in the adult population in the Czech Republic in connection with the COVID-19 disease. Methods: For this purpose, an online questionnaire Neurocovid was developed. The data presented were collected during the period of June 6–August 30, 2021. Results: The questionnaire was fi lled in by 1,012 individuals aged between 18–79 years (average age 45.6 ±12.88 years, median age 45 years, 65% female). Regional coverage of the Czech Republic mostly corresponded with the demographic distribution of the population. The most common new neurological symptoms that occurred in connection with COVID-19 were cognitive changes such as “slow thinking”, memory difficulties, lack of concentration, speech disorders and disorientation. About 70% of the participants reported at least one of these symptoms. Similar frequency was noted for sleep disorders which were present in more than 70% of the participants. Both groups of symptoms also had a higher tendency to persist long-term. Cognitive changes persisted for over 3 months in 46%, whereas sleep disorders in 72%. Another frequent neurological symptom was olfactory/gustatory dysfunction, which was observed by 67% of the participants. Other symptoms included vertigo (32%), tingling in the body/ limbs (27%), clumsiness/loss of stability while walking (20%), tinnitus (15%), issues with eyesight (14%), and tremor (13%). We did not find a correlation between the severity of the acute phase of the COVID-19 disease and the number or type of new neurological symptoms. Conclusion: This nation-wide online survey of a representative group of the Czech population confirmed a variety of neurological symptoms that occur in connection with COVID-19. The Neurocovid questionnaire should be distributed further to increase data quality and provide an insight into the long-term development of these symptoms.

Keywords:

memory – cognitive dysfunction – sleep disorders – SARS-CoV-2 – COVID-19 – coronavirus – neurological symptoms – post- -Covid syndrome – long-term Covid

Zdroje

1. World Health Organization. WHO Coronavirus (COVID-19) Dashboard. [online]. Dostupné z: https:/ / covid19.who. int.

2. Paterson RW, Brown RL, Benjamin L et al. The emerging spectrum of COVID-19 neurology: clinical, radiological and laboratory findings. Brain 2020; 143(10): 3104– 3120. doi: 10.1093/ brain/ awaa240.

3. Varatharaj A, Thomas N, Ellul MA et al. Neurological and neuropsychiatric complications of COVID-19 in 153 patients: a UK-wide surveillance study. Lancet Psychiatry 2020; 7(10): 875–882. doi: 10.1016/ S2215-0366(20)30 287-X.

4. Helms J, Kremer S, Merdji H et al. Neurologic features in severe SARS-CoV-2 infection. N Engl J Med 2020; 382(23): 2268–2270. doi: 10.1056/ NEJMc2008597.

5. Di Carlo DT, Montemurro N, Petrella G et al. Exploring the clinical association between neurological symptoms and COVID-19 pandemic outbreak: a systematic review of current literature. J Neurol 2021; 268(5): 1561–1569. doi: 10.1007/ s00415-020-09978-y.

6. Li W, Zhang C, Sui J et al. Receptor and viral determinants of SARS-coronavirus adaptation to human ACE2. EMBO J 2005; 24(8): 1634–1643. doi: 10.1038/ sj.emboj. 7600640.

7. Duvernoy HM, Risold PY. The circumventricular organs: an atlas of comparative anatomy and vascularization. Brain Res Rev 2007; 56(1): 119–147. doi: 10.1016/ j.brainresrev. 2007.06.002.

8. Rogers JP, Watson CJ, Badenoch J et al. Neurology and neuropsychiatry of COVID-19: a systematic review and meta-analysis of the early literature reveals frequent CNS manifestations and key emerging narratives. J Neurol Neurosurg Psychiatry 2021; 92(9): 932–941. doi: 10.1136/ jnnp-2021-326405.

9. Beghi E, Helbok R, Oztturk S et al. Short- and longterm outcome and predictors in an international cohort of patients with neuro COVID-19. Eur J Neurol 2022; 29(6): 1663–1684. doi: 10.1111/ ene.15293.

10. Rass V, Beer R, Schiefecker AJ et al. Neurological outcomes one year after COVID-19 diagnosis: a prospective longitudinal cohort study. Eur J Neurol 2022; 29(6): 1685– 1696. doi: 10.1111/ ene.15307.

11. Genzor S, Sova M, Mizera J et al. Poruchy čichu po COVID-19 – diagnostika, význam a léčba. Cesk Slov Neurol N 2021; 84/ 117(4): 347–352. doi: 10.48095/ cccsnn2021347.

12. Ehler E, Medová N, Wurst Z et al. COVID-19 u nemocných s myasthenia gravis. Cesk Slov Neurol N 2021; 84/ 117(4): 393–396. doi: 10.48095/ cccsnn2021393.

13. Herzig R, Mikulík R, Tomek A et al. COVID-19 a iktus. Cesk Slov Neurol N 2021; 84/ 117(1): 31–37. doi: 10.48095/ cccsnn202131.

14. Adamová B, Škorňa M, Jurisová K et al. Guillain-Barrého syndrom u pacienta s COVID-19. Cesk Slov Neurol N 2021; 84(6): 589–590. doi: 10.48095/ cccsnn2021589.

15. Ostrý S, Keller J, Sobek O et al. Encefalopatie při infekci COVID-19 s odezvou na léčbu intravenózními imunoglobuliny. Cesk Slov Neurol N 2020; 83/ 116(6): 640– 642. doi: 10.48095/ cccsnn2020640.

16. Bartoš H, Fabianová L, Dlouhý P et al. COVID-19 asociovaná myelitida – kazuistika vzácné komplikace závažné SARS-CoV-2 infekce. Cesk Slov Neurol N 2021; 84/ 117(4): 410–412. doi: 10.48095/ cccsnn2021410.

17. Neurocovid. [online]. Dostupné z URL: https:/ / www. neurocovid.cz/ .

18. Český statistický úřad. První výsledky sčítání lidu, domů a bytů 2021. [online]. Dostupné z URL: https:/ / vdb. czso.cz/ vdbvo2/ faces/ index.jsf?page=vystup-objekt&p vokc=&katalog=33477&pvo=SLD210052&z=T.

19. Goërtz YMJ, Van Herck M, Delbressine JM et al. Persistent symptoms 3 months after a SARS-CoV-2 infection: the post-COVID-19 syndrome? ERJ Open Res 2020; 6(4): 00542–02020. doi: 10.1183/ 23120541.00542-2020.

20. Mahase E. Covid-19: what do we know about “long covid”? BMJ 2020; 370: m2815. doi: 10.1136/ bmj.m2815.

21. Carfì A, Bernabei R, Landi F et al. Persistent symptoms in patients after acute COVID-19. JAMA 2020; 324(6): 603– 605. doi: 10.1001/ jama.2020.12603.

22. Huang C, Huang L, Wang Y et al. 6-month consequences of COVID-19 in patients discharged from hospital: a cohort study. The Lancet 2021; 397(10270): 220–232. doi: 10.1016/ S0140-6736(20)32656-8.

23. Lechien JR, Chiesa-Estomba CM, De Siati DR et al. Olfactory and gustatory dysfunctions as a clinical presentation of mild-to-moderate forms of the coronavirus disease (COVID-19): a multicenter European study. Eur Arch Otorhinolaryngol 2020; 277(8): 2251–2261. doi: 10.1007/ s00405-020-05965-1.

24. Avula A, Nalleballe K, Narula N et al. COVID-19 presenting as stroke. Brain Behav Immun 2020; 87: 115–119. doi: 10.1016/ j.bbi.2020.04.077.

25. Beyrouti R, Adams ME, Benjamin L et al. Characteristics of ischaemic stroke associated with COVID-19. J Neurol Neurosurg Psychiatry 2020; 91(8): 889–891. doi: 10.1136/ jnnp-2020-323586.

26. Mandal S, Barnett J, Brill SE et al. “Long-COVID”: a cross-sectional study of persisting symptoms, biomarker and imaging abnormalities following hospitalisation for COVID-19. Thorax 2021; 76(4): 396–398. doi: 10.1136/ thoraxjnl-2020-215818.

27. Sudre CH, Murray B, Varsavsky T et al. Attributes and predictors of long COVID. Nat Med 2021; 27(4): 626–631. doi: 10.1038/ s41591-021-01292-y.

28. Crook H, Raza S, Nowell J et al. Long covid-mechanisms, risk factors, and management. BMJ 2021; 374: n1648. doi: 10.1136/ bmj.n1648.

29. Both LM, Zoratto G, Calegaro VC et al. COVID-19 pandemic and social distancing: economic, psychological, family, and technological eff ects. Trends Psychiatry Psychother 2021; 43(2): 85–91. doi: 10.47626/ 2237-6089-2020-0085.

30. Winkler P, Mohrova Z, Mlada K et al. Prevalence of current mental disorders before and during the second wave of COVID-19 pandemic: an analysis of repeated nationwide cross-sectional surveys. J Psychiatr Res 2021; 139: 167–171. doi: 10.1016/ j.jpsychires.2021.05.032.

31. Søraas A, Bø R, Kalleberg KT et al. Self-reported memory problems 8 months after COVID-19 infection. JAMA Netw Open 2021; 4(7): e2118717–e2118717. doi: 10.1001/ jamanetworkopen.2021.18717.

32. Salluh JIF, Wang H, Schneider EB et al. Outcome of delirium in critically ill patients: systematic review and meta-analysis. BMJ 2015; 350: h2538. doi: 10.1136/ bmj. h2538.

33. Bartoš A. Inovativní a původní české kognitivní testy Amnesia Light and Brief Assessment a Pojmenování obrázků a jejich vybavení a vyšetřovací metody v diagnostice kognitivních poruch a demencí. Med Praxi 2022; 19(1): 50–57. doi: 10.36290/ med.2022.007.

34. Bartoš A, Polanská H. Dvě původní české zkoušky k vyšetření paměti za tři minuty – Amnesia Light and Brief Assessment (ALBA). Cesk Slov Neurol N 2019; 82/ 115(4): 420–429. doi: 10.14735/ amcsnn2019420.

35. Bartoš A. Netestuj, ale POBAV: písemné záměrné Pojmenování OBrázků A jejich Vybavení jako krátká kognitivní zkouška. Cesk Slov Neurol N 2016; 79/ 112(6): 671–679.

36. Bartoš A. Pamatujte na POBAV – krátký test pojmenování obrázků a jejich vybavení sloužící ke včasnému záchytu kognitivních poruch. Neurol Praxi 2018; 19 (Suppl 1): 5–10.

37. Bartoš A, Polanská H. Správná a chybná pojmenování obrázků pro náročnější test písemného Pojmenování obrázků a jejich vybavení (dveřní POBAV). Cesk Slov Neurol N 2021; 84/ 117(2): 151–163. doi: 10.48095/ cccsnn2021151.